{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:43:29Z","timestamp":1793317409200,"version":"4.5.0"},"reference-count":175,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The global epidemiology and burden of hyperkalaemia in patients with chronic kidney disease (CKD) are unclear due to the inconsistent definitions of hyperkalaemia. The combination of adverse effects and interaction between comorbidity and pharmacotherapies, such as renin\u2013angiotensin\u2013aldosterone system inhibitors (RAASi), justify a systematic understanding of this common complication of CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic literature review aimed to identify and descriptively summarize the evidence on hyperkalaemia risk factors and associated characteristics in adult CKD patients, including the effects of sub-optimal RAASi. Medline\u00ae and Embase\u00ae databases were searched from January 2000 to April 2024, with additional hand searching. Publications were screened by two independent reviewers. Data were extracted by one reviewer and verified by another reviewer; study quality assessment was also conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 138 studies described in 145 publications met the eligibility criteria. The published literature revealed varying prevalence of hyperkalaemia amongst inconsistent definitions and a significant increase in the prevalence and incidence of hyperkalaemia among patients with CKD, regardless of RAASi treatment. Hyperkalaemia was associated with adverse outcomes and increased hospital resource use. Additionally, studies pointed to negative health and economic outcomes due to sub-optimal RAASi dosing in CKD patients with hyperkalaemia, as well as in those with CKD and comorbid heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review expands on current research, offering a new perspective specifically focused on CKD patients and wider clinical and economic outcomes. Identification of wider clinical and economic consequences of hyperkalaemia in CKD patients, and the interplay between these risks and the risks of sub-optimal RAASi dosing, justify the need for future research. Clinicians should exercise caution when managing this condition in this complex patient group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfaf127","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T07:38:18Z","timestamp":1745825898000},"source":"Crossref","is-referenced-by-count":12,"title":["The burden of hyperkalaemia in chronic kidney disease: a systematic literature review"],"prefix":"10.1093","volume":"18","author":[{"given":"J\u00fcrgen","family":"Floege","sequence":"first","affiliation":[{"name":"Division of Nephrology and Dept of Cardiology, RWTH Aachen University , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H","family":"Frankel","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin F","family":"Erickson","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine , TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketevan","family":"Rtveladze","sequence":"additional","affiliation":[{"name":"IQVIA , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Punekar","sequence":"additional","affiliation":[{"name":"IQVIA , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5212-9063","authenticated-orcid":false,"given":"Jahangir Nabi","family":"Mir","sequence":"additional","affiliation":[{"name":"IQVIA , Gurugram, Haryana ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Walters","sequence":"additional","affiliation":[{"name":"IQVIA , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ehm","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-2223","authenticated-orcid":false,"given":"James","family":"Fotheringham","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"2025052606264278600_bib1","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical management of hyperkalemia","volume":"96","author":"Palmer","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2025052606264278600_bib2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025052606264278600_bib3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ckj\/sfab243","article-title":"How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies","volume":"15","author":"Humphrey","year":"2022","journal-title":"Clin Kidney J"},{"key":"2025052606264278600_bib4","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"2025052606264278600_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.resuscitation.2021.02.011","article-title":"European Resuscitation Council Guidelines: cardiac arrest in special circumstances","volume":"161","author":"Lott","year":"2021","journal-title":"Resuscitation"},{"key":"2025052606264278600_bib6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00467-010-1699-3","article-title":"Pathogenesis, diagnosis and management of hyperkalemia","volume":"26","author":"Lehnhardt","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"2025052606264278600_bib7","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1503\/cmaj.100461","article-title":"Management of patients with acute hyperkalemia","volume":"182","author":"Elliott","year":"2010","journal-title":"Can Med Assoc J"},{"key":"2025052606264278600_bib8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"key":"2025052606264278600_bib9","doi-asserted-by":"publisher","first-page":"s31","DOI":"10.1590\/1806-9282.66.s1.31","article-title":"Hyperkalemia in chronic kidney disease","volume":"66","author":"Watanabe","year":"2020","journal-title":"Rev Assoc Med Bras"},{"key":"2025052606264278600_bib10","first-page":"40","article-title":"Hyperkalemia in adults: review of a common electrolyte imbalance","volume":"27","author":"Douglas","year":"2017","journal-title":"Clin Rev"},{"key":"2025052606264278600_bib11","first-page":"iii692","article-title":"Comparison of potassium values before and after patiromer initiation among patients receiving chronic hemodialysis in the United States","volume-title":"Nephrol Dial Transplant","author":"Rowan","year":"2017"},{"key":"2025052606264278600_bib12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2215\/CJN.01150112","article-title":"Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic","volume":"7","author":"Sarafidis","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025052606264278600_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/IJNRD.S401623","article-title":"Hyperkalemia and the use of new potassium binders a single center experience from Vestfold Norway (the PotBind study)","volume":"16","author":"Bjune","year":"2023","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2025052606264278600_bib14","doi-asserted-by":"publisher","first-page":"iii51","DOI":"10.1093\/ndt\/gfz213","article-title":"Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia","volume":"34","author":"Bianchi","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2025052606264278600_bib15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrneph.2014.168","article-title":"Management of hyperkalaemia in chronic kidney disease","volume":"10","author":"Kovesdy","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"2025052606264278600_bib16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40620-021-01070-6","article-title":"Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease","volume":"35","author":"Santoro","year":"2022","journal-title":"J Nephrol"},{"key":"2025052606264278600_bib17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-019-1228-y","article-title":"The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease","volume":"20","author":"Evans","year":"2019","journal-title":"BMC Nephrol"},{"key":"2025052606264278600_bib18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s11096-013-9830-8","article-title":"Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia","volume":"35","author":"Kuijvenhoven","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"2025052606264278600_bib19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/ejhf.2612","article-title":"An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum","volume":"24","author":"Burton","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025052606264278600_bib20","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"2025052606264278600_bib21","volume-title":"Guidance for Undertaking Reviews in Health Care. Systematic Reviews CRD","author":"Centre for Reviews and Dissemination (CRD)","year":"2008"},{"key":"2025052606264278600_bib22","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"2025052606264278600_bib23","volume-title":"Single Technology Appraisal: User Guide for Company Evidence Submission Template","author":"National Institute for Health and Care Excellence (NICE)","year":"2015"},{"key":"2025052606264278600_bib24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025052606264278600_bib25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Commun Health"},{"key":"2025052606264278600_bib26","first-page":"885","article-title":"Impact of hyperkalemia on hospitalization days in advanced chronic kidney disease patients with Type-2 diabetes mellitus: a prospective study","volume":"39","author":"Li","year":"2023","journal-title":"Pakistan J Med Sci"},{"key":"2025052606264278600_bib27","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1016\/j.ekir.2023.02.358","article-title":"WCN23-1101 Instantaneous and persistent elevation of serum potassium and progression of chronic kidney disease, a single center-based cohort study","volume":"8","author":"Wang","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025052606264278600_bib28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/jcm11010244","article-title":"Correlation between hyperkalemia and the duration of several hospitalizations in patients with chronic kidney disease","volume":"11","author":"Calabrese","year":"2022","journal-title":"J Clin Med"},{"key":"2025052606264278600_bib29","doi-asserted-by":"publisher","first-page":"855395","DOI":"10.3389\/fpubh.2022.855395","article-title":"the impact of hyperkalemia on mortality and healthcare resource utilization among patients with chronic kidney disease: a matched cohort study in China","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Public Health"},{"key":"2025052606264278600_bib30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/jphsr\/rmaa004","article-title":"Healthcare resource utilization and costs associated with hyperkalemia in a large managed care population","volume":"12","author":"Sharma","year":"2021","journal-title":"J Pharm Health Serv Res"},{"key":"2025052606264278600_bib31","first-page":"274","article-title":"Cardiovascular and renal outcomes associated with hyperkalemia in chronic kidney disease: a hospital-based cohort study","volume":"5","author":"Kohsaka","year":"2021","journal-title":"Mayo Clinic Proc"},{"key":"2025052606264278600_bib32","doi-asserted-by":"publisher","first-page":"e14326","DOI":"10.1111\/ijcp.14326","article-title":"Health-related quality of life and lifestyle changes in patients with chronic kidney disease and hyperkalaemia: real-world data from the US, five European countries and China","volume":"75","author":"Grandy","year":"2021","journal-title":"Int J Clin Pract"},{"key":"2025052606264278600_bib33","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/CEOR.S267063","article-title":"A model to predict risk of hyperkalemia in patients with chronic kidney disease using a large administrative claims database","volume":"12","author":"Sharma","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"2025052606264278600_bib34","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.xkme.2020.09.003","article-title":"Clinical and economic burden of hyperkalemia: a nationwide hospital-based cohort study in Japan","volume":"2","author":"Kanda","year":"2020","journal-title":"Kidney Medicine"},{"key":"2025052606264278600_bib35","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/CLEP.S253745","article-title":"Real-world epidemiology of potassium derangements among chronic cardiovascular, metabolic and renal conditions: a population-based analysis","volume":"12","author":"Jimenez-Marrero","year":"2020","journal-title":"Clin Epidemiol"},{"key":"2025052606264278600_bib36","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.ekir.2020.06.004","article-title":"Postdischarge health care costs and readmission in patients with hyperkalemia-related hospitalizations","volume":"5","author":"Betts","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2025052606264278600_bib37","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/03007995.2020.1775072","article-title":"Prevalence and economic burden of hyperkalemia in the United States Medicare population","volume":"36","author":"Mu","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"2025052606264278600_bib38","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1016\/j.ekir.2021.03.344","article-title":"Pos-328 The burden of hyperkalemia in patients with chronic kidney disease: a report from the DISCOVER CKD retrospective cohort","volume":"6","author":"James","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025052606264278600_bib39","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1016\/j.ekir.2022.01.325","article-title":"Pos-305 Hospitalizations and length of stay in patients with CKD with and without hyperkalemia: a report from the DISCOVER CKD retrospective cohort","volume":"7","author":"James","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025052606264278600_bib40","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/ndt\/gfx312","article-title":"Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study","volume":"33","author":"Thomsen","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025052606264278600_bib41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12882-018-1007-1","article-title":"Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: New risk equations using the UK clinical practice research datalink","volume":"19","author":"Furuland","year":"2018","journal-title":"BMC Nephrol"},{"key":"2025052606264278600_bib42","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s12325-022-02420-x","article-title":"The increased clinical and economic burden of hyperkalemia in Medicare patients admitted to long-term care settings","volume":"40","author":"Neuenschwander","year":"2023","journal-title":"Adv Ther"},{"key":"2025052606264278600_bib43","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ekir.2017.11.003","article-title":"The cost of hyperkalemia in the United States","volume":"3","author":"Betts","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2025052606264278600_bib44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2215\/CJN.01730215","article-title":"Association between serum potassium and outcomes in patients with reduced kidney function","volume":"11","author":"Luo","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025052606264278600_bib45","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000437151","article-title":"Serum potassium, end-stage renal disease and mortality in chronic kidney disease","volume":"41","author":"Nakhoul","year":"2015","journal-title":"Am J Nephrol"},{"key":"2025052606264278600_bib46","doi-asserted-by":"publisher","first-page":"e67140","DOI":"10.1371\/journal.pone.0067140","article-title":"Hypokalemia, its contributing factors and renal outcomes in patients with chronic kidney disease","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"2025052606264278600_bib47","first-page":"C8","article-title":"Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race","volume":"120","author":"Hayes","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2025052606264278600_bib48","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","article-title":"Predictors of hyperkalemia and death in patients with cardiac and renal disease","volume":"109","author":"Jain","year":"2012","journal-title":"Am J Cardiol"},{"key":"2025052606264278600_bib49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12882-017-0710-7","article-title":"Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care\u2014The NephroTest study","volume":"18","author":"Wagner","year":"2017","journal-title":"BMC Nephrol"},{"key":"2025052606264278600_bib50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"2025052606264278600_bib51","doi-asserted-by":"publisher","first-page":"762","DOI":"10.2215\/CJN.05850809","article-title":"Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study","volume":"5","author":"Korgaonkar","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025052606264278600_bib52","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000325226","article-title":"Hypokalemia is associated with increased mortality rate in chronic hemodialysis patients","volume":"32","author":"Hwang","year":"2011","journal-title":"Blood Purif"},{"key":"2025052606264278600_bib53","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/imj.14970","article-title":"Serum potassium abnormalities in chronic kidney disease: prevalence, patient characteristics and clinical outcomes","volume":"51","author":"Brookes","year":"2021","journal-title":"Intern Med J"},{"key":"2025052606264278600_bib54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00380-022-02192-y","article-title":"Serum potassium in elderly heart failure patients as a predictor of readmission within 1 year","volume":"38","author":"Shang","year":"2022","journal-title":"Heart Vessels"},{"key":"2025052606264278600_bib55","first-page":"312","article-title":"Impact on clinical outcomes and health costs of deranged potassium levels in patients with chronic cardiovascular, metabolic, and renal conditions","volume":"74","author":"Jimenez-Marrero","year":"2021","journal-title":"Rev Esp Cardiol"},{"key":"2025052606264278600_bib56","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s10157-020-02010-7","article-title":"Association between serum potassium levels and adverse outcomes in chronic kidney disease: the Fukushima CKD cohort study","volume":"25","author":"Tanaka","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2025052606264278600_bib57","doi-asserted-by":"publisher","first-page":"1084442","DOI":"10.3389\/fphar.2023.1084442","article-title":"Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease\u2014\u2014balance of efficacy and risk","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025052606264278600_bib58","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12882-022-03054-5","article-title":"Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia","volume":"24","author":"Kanda","year":"2023","journal-title":"BMC Nephrol"},{"key":"2025052606264278600_bib59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ejhf.2740","article-title":"The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure","volume":"25","author":"Lin","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025052606264278600_bib60","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1681\/ASN.20223311S1677c","article-title":"Safety and efficacy of maximally tolerated RAS therapy alone or in combination with spironolactone in diabetic kidney disease: effect on proteinuria and eGFR in the MRA-ACE trial","volume":"33","author":"Tumlin","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025052606264278600_bib61","first-page":"547","article-title":"A comparative study of the prevalence of hyperkalemia with the use of angiotensinconverting enzyme inhibitors versus angiotensin receptor blockers","volume":"5","author":"Sadjadi","year":"2009","journal-title":"Ther Clin Risk Manage"},{"key":"2025052606264278600_bib62","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"},{"key":"2025052606264278600_bib63","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1001\/archinternmed.2009.284","article-title":"Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy","volume":"169","author":"Weinberg","year":"2009","journal-title":"Arch Intern Med"},{"key":"2025052606264278600_bib64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0002-9343(01)01068-3","article-title":"Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients","volume":"112","author":"Knoll","year":"2002","journal-title":"Am J Med"},{"key":"2025052606264278600_bib65","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0895-7061(02)03147-3","article-title":"Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment","volume":"16","author":"Hayashi","year":"2003","journal-title":"Am J Hypertens"},{"key":"2025052606264278600_bib66","doi-asserted-by":"publisher","first-page":"e0218739","DOI":"10.1371\/journal.pone.0218739","article-title":"Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients\u2014A population-based cohort study","volume":"14","author":"Adelborg","year":"2019","journal-title":"PLoS One"},{"key":"2025052606264278600_bib67","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3109\/08860220903216121","article-title":"Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease","volume":"31","author":"Sengul","year":"2009","journal-title":"Ren Fail"},{"key":"2025052606264278600_bib68","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"2025052606264278600_bib69","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ahj.2016.03.024","article-title":"Long-term changes of renal function in relation to ace inhibitor\/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease","volume":"178","author":"Frohlich","year":"2016","journal-title":"Am Heart J"},{"key":"2025052606264278600_bib70","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (eplerenone in mild patients hospitalization and survival study in heart failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2025052606264278600_bib71","first-page":"S2","article-title":"Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure","volume":"23","author":"Polson","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2025052606264278600_bib72","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/ndt\/gfz263","article-title":"Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population","volume":"36","author":"Wetmore","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2025052606264278600_bib73","doi-asserted-by":"publisher","first-page":"101751","DOI":"10.1016\/j.eclinm.2022.101751","article-title":"Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study","volume":"55","author":"Yang","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2025052606264278600_bib74","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s00228-020-03069-7","article-title":"Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease","volume":"77","author":"Buckallew","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2025052606264278600_bib75","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0011-393X(02)80027-3","article-title":"Evaluation of long-term efficacy and tolerability of irbesartan in elderly hypertensive patients with renal impairment in an open-label study","volume":"63","author":"De Rosa","year":"2002","journal-title":"Curr Ther Res"},{"key":"2025052606264278600_bib76","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/ckj\/sfac077","article-title":"Prescription patterns of sodium and calcium polystyrene sulfonate in patients with hyperkalemia and chronic kidney disease receiving RAAS inhibitors","volume":"15","author":"Ren","year":"2022","journal-title":"Clin Kidney J"},{"key":"2025052606264278600_bib77","doi-asserted-by":"publisher","first-page":"824095","DOI":"10.3389\/fcvm.2022.824095","article-title":"RAAS inhibitor prescription and hyperkalemia event in patients with chronic kidney disease: a single-center retrospective study","volume":"9","author":"Riccio","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025052606264278600_bib78","first-page":"5158","article-title":"Efficacy and safety of esaxerenone in hypertensive patients with diabetic kidney disease: a multicenter, open-label, prospective study","volume":"39","author":"Uchida","year":"2022","journal-title":"Adv Ther"},{"key":"2025052606264278600_bib79","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/ndt\/gfaa085","article-title":"Direct Renin Inhibition in Non-diabetic chronic Kidney disease (DRINK): a prospective randomized trial","volume":"36","author":"Tang","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2025052606264278600_bib80","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"2025052606264278600_bib81","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"2025052606264278600_bib82","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/pds.1923","article-title":"Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril","volume":"19","author":"Johnson","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025052606264278600_bib83","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s11606-009-1228-x","article-title":"Diabetes and drug-associated hyperkalemia: effect of potassium monitoring","volume":"25","author":"Raebel","year":"2010","journal-title":"J Gen Intern Med"},{"key":"2025052606264278600_bib84","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/ndt\/gfp547","article-title":"Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease","volume":"25","author":"Frimodt-Moller","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2025052606264278600_bib85","first-page":"507","article-title":"A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl","volume":"23","author":"Taheri","year":"2012"},{"key":"2025052606264278600_bib86","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/1756-0500-6-306","article-title":"Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study","volume":"6","author":"Espinel","year":"2013","journal-title":"BMC Res Notes"},{"key":"2025052606264278600_bib87","doi-asserted-by":"publisher","first-page":"e26904","DOI":"10.1371\/journal.pone.0026904","article-title":"Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. a randomized cross-over study","volume":"6","author":"Boesby","year":"2011","journal-title":"PLoS One"},{"key":"2025052606264278600_bib88","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","article-title":"The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease","volume":"73","author":"Edwards","year":"2012","journal-title":"Brit J Clin Pharmacol"},{"key":"2025052606264278600_bib89","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijcard.2017.03.080","article-title":"Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: a nationwide population-based study","volume":"238","author":"Tseng","year":"2017","journal-title":"Int J Cardiol"},{"key":"2025052606264278600_bib90","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025052606264278600_bib91","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/MAJ.0b013e3181836ac7","article-title":"Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis","volume":"336","author":"Maddirala","year":"2008","journal-title":"Am J Med Sci"},{"key":"2025052606264278600_bib92","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/01.mbp.0000172708.97534.15","article-title":"Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease","volume":"10","author":"Rysava","year":"2005","journal-title":"Blood Press Monit"},{"key":"2025052606264278600_bib93","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025052606264278600_bib94","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025052606264278600_bib95","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025052606264278600_bib96","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1681\/ASN.20223311S1678a","article-title":"Effect of finerenone on CKD outcomes in type 2 diabetes: a Chinese subgroup analysis of the FIDELIO-DKD study. Kidney week","volume":"33","author":"Zhang","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025052606264278600_bib97","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"2025052606264278600_bib98","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025052606264278600_bib99","doi-asserted-by":"publisher","first-page":"e888","DOI":"10.2337\/dc21-1944","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline hba1c and insulin use: an analysis from the FIDELIO-DKD study","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2025052606264278600_bib100","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000531997","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes: the FIDELIO-DKD subgroup from China","volume":"9","author":"Zhang","year":"2023","journal-title":"Kidney Dis"},{"key":"2025052606264278600_bib101","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/phar.2051","article-title":"Incidence of and risk factors for severe adverse events in elderly patients taking angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers after an acute myocardial infarction","volume":"38","author":"Fang","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2025052606264278600_bib102","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000500925","article-title":"Is chronic kidney disease progression influenced by the type of renin-angiotensin-system blocker used?","volume":"143","author":"Silvarino","year":"2019","journal-title":"Nephron"},{"key":"2025052606264278600_bib103","doi-asserted-by":"publisher","first-page":"e012655","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom","volume":"8","author":"Linde","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025052606264278600_bib104","first-page":"86","article-title":"A retrospective study on the potential drug interaction between angiotensin converting enzyme inhibitor or angiotensin receptor antagonist and other drugs in end-stage chronic renal failure patients","volume":"3","author":"Iskandar","year":"2012","journal-title":"Int Res J Pharmacy"},{"key":"2025052606264278600_bib105","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ekir.2019.05.018","article-title":"Hyperkalemia in real-world patients under continuous medical care in Japan","volume":"4","author":"Kashihara","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2025052606264278600_bib106","doi-asserted-by":"publisher","first-page":"e0184402","DOI":"10.1371\/journal.pone.0184402","article-title":"Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors","volume":"12","author":"Saito","year":"2017","journal-title":"PLoS One"},{"key":"2025052606264278600_bib107","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2025052606264278600_bib108","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.2337\/dc10-0833","article-title":"Impact of baseline renal function on the efficacy and safety of Aliskiren added to losartan in patients with type 2 diabetes and nephropathy","volume":"33","author":"Persson","year":"2010","journal-title":"Diabetes Care"},{"key":"2025052606264278600_bib109","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000369138","article-title":"Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease","volume":"128","author":"Gwoo","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"2025052606264278600_bib110","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025052606264278600_bib111","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.2215\/CJN.12371214","article-title":"The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial","volume":"10","author":"Walsh","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025052606264278600_bib112","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/phar.2633","article-title":"Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI\/ARBs in patients with diabetic kidney disease","volume":"41","author":"An","year":"2021","journal-title":"Pharmacotherapy"},{"key":"2025052606264278600_bib113","doi-asserted-by":"publisher","first-page":"632978","DOI":"10.3389\/fphar.2021.632978","article-title":"Spironolactone improves the all-cause mortality and re-hospitalization rates in acute myocardial infarction with chronic kidney disease patients","volume":"12","author":"Qu","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025052606264278600_bib114","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.2215\/CJN.01930221","article-title":"Effects of spironolactone and chlorthalidone on cardiovascular structure and function in chronic kidney disease: a randomized, open-label trial","volume":"16","author":"Edwards","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025052606264278600_bib115","first-page":"46","article-title":"Initiation of sacubitril\/valsartan in patients with renal impairment early after acute decompensated heart failure in the TRANSITION study","volume":"23","author":"Straburzynska-Migaj","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025052606264278600_bib116","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00004872-200018010-00013","article-title":"Safety of the combination of valsartan and benazepril in patients with chronic renal disease","volume":"18","author":"Ruilope","year":"2000","journal-title":"J Hypertens"},{"key":"2025052606264278600_bib117","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/00005344-200109000-00017","article-title":"Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study","volume":"38","author":"De Rosa","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025052606264278600_bib118","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int"},{"key":"2025052606264278600_bib119","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int"},{"key":"2025052606264278600_bib120","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease: a randomized double-blind trial","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"2025052606264278600_bib121","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/1470320313507122","article-title":"The effect of renin-angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia","volume":"15","author":"Lee","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2025052606264278600_bib122","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/21556660.2016.1252380","article-title":"Effect of telmisartan on kidney function in patients with chronic kidney disease: an observational study","volume":"5","author":"Agrawal","year":"2016","journal-title":"J Drug Assess"},{"key":"2025052606264278600_bib123","first-page":"129","article-title":"A retrospective aliskiren and losartan study in non-diabetic chronic kidney disease","volume":"2","author":"Woo","year":"2013","journal-title":"World J Nephrol"},{"key":"2025052606264278600_bib124","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","article-title":"Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?","volume":"34","author":"Yildirim","year":"2012","journal-title":"Ren Fail"},{"key":"2025052606264278600_bib125","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/jhh.2011.60","article-title":"Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease","volume":"26","author":"Pisoni","year":"2012","journal-title":"J Hum Hypertens"},{"key":"2025052606264278600_bib126","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/jcpt.12720","article-title":"Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments","volume":"43","author":"Hirai","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"2025052606264278600_bib127","doi-asserted-by":"publisher","first-page":"e0213192","DOI":"10.1371\/journal.pone.0213192","article-title":"Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study","volume":"14","author":"Jun","year":"2019","journal-title":"PLoS One"},{"key":"2025052606264278600_bib128","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.nefro.2018.11.011","article-title":"Epidemiology of hyperkalemia in chronic kidney disease","volume":"39","author":"Belmar Vega","year":"2019","journal-title":"Nefrologia"},{"key":"2025052606264278600_bib129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2025052606264278600_bib130","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jash.2010.09.006","article-title":"Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy","volume":"4","author":"Heshka","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"2025052606264278600_bib131","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ahj.2023.01.002","article-title":"Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor","volume":"258","author":"Johnson","year":"2023","journal-title":"Am Heart J"},{"key":"2025052606264278600_bib132","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025052606264278600_bib133","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study","volume":"80","author":"Leon","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2025052606264278600_bib134","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41371-021-00625-1","article-title":"A comparative study assessing the incidence and degree of hyperkalemia in patients on angiotensin-converting enzyme inhibitors versus angiotensin-receptor blockers","volume":"36","author":"Salik","year":"2022","journal-title":"J Hum Hypertens"},{"key":"2025052606264278600_bib135","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5414\/CNP73139","article-title":"Renoprotective effects of telmisartan in patients with advanced chronic kidney disease","volume":"73","author":"Tokunaga","year":"2010","journal-title":"Clin Nephrol"},{"key":"2025052606264278600_bib136","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin\u2013angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"key":"2025052606264278600_bib137","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1681\/ASN.2020050682","article-title":"Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study","volume":"32","author":"Fu","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025052606264278600_bib138","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin\u2013angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2025052606264278600_bib139","doi-asserted-by":"publisher","first-page":"S327","DOI":"10.1016\/j.ekir.2024.02.633","article-title":"WCN24-2118 Hyperkalaemia in patients with chronic kidney disease and heart failure","volume":"9","author":"Parmar","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025052606264278600_bib140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2024\/5694131","article-title":"The prevalence and risk factors of hyperkalemia in the outpatient setting","volume":"2024","author":"Sevamontree","year":"2024","journal-title":"Int J Nephrol"},{"key":"2025052606264278600_bib141","doi-asserted-by":"publisher","first-page":"sfad212","DOI":"10.1093\/ckj\/sfad212","article-title":"Gender-specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men","volume":"17","author":"Valdivielso","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025052606264278600_bib142","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4274\/imj.galenos.2023.55889","article-title":"Hyperkalemia: a cause of non-adherence to renin-angiotensin-aldosterone system inhibitors in chronic kidney disease: a retrospective study","volume":"24","author":"G\u00fcl\u00e7i\u00e7ek","year":"2023","journal-title":"Istanbul Med J"},{"key":"2025052606264278600_bib143","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/clc.24114","article-title":"Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry","volume":"46","author":"Zhou","year":"2023","journal-title":"Clin Cardiol"},{"key":"2025052606264278600_bib144","article-title":"Frequency of hyperkalaemia in non-dialysis dependent chronic kidney disease (CKD) patients","volume":"34","author":"Qadir","year":"2023","journal-title":"Medical Forum Monthly"},{"key":"2025052606264278600_bib145","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.ajkd.2023.03.008","article-title":"Serum potassium and risk of death or kidney replacement therapy in older people with CKD stages 4-5: eight-year follow-up","volume":"82","author":"de Rooij","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2025052606264278600_bib146","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1681\/ASN.20233411S1397a","article-title":"Prevalence and factors associated with hyperkalemia in outpatients with CKD","volume":"34","author":"Perez-Navarro","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025052606264278600_bib147","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1681\/ASN.20233411S1190d","article-title":"REVOLUTIONIZE III: consequences of recurrent hyperkalemia on healthcare resource utilization and cost","volume":"34","author":"Bakris","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025052606264278600_bib148","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.ekir.2024.02.028","article-title":"WCN24-2258 Serum potassium profile and associated factors in hemodialysis patients: single center study","volume":"9","author":"Gaol","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025052606264278600_bib149","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1681\/ASN.20233411S1379b","article-title":"Association between reduced RAASi therapy and progression to ESKD in hyperkalemic CKD patients","volume":"34","author":"Rastogi","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025052606264278600_bib150","doi-asserted-by":"publisher","first-page":"i668","DOI":"10.1093\/ndt\/gfad063c_3068","article-title":"Potassium levels and eGFR do not predict severe hyperkalemia following spironolactone introduction in patients with CKD at high risk of hyperkalemia","volume":"38","author":"Marup","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025052606264278600_bib151","doi-asserted-by":"publisher","first-page":"i665","DOI":"10.1093\/ndt\/gfad063c_5705","article-title":"Efficacy and safety of sacubitril\/valsartan in patients with stage 3B-5 CKD and hypertension","volume":"38","author":"Zhou","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025052606264278600_bib152","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0735-1097(23)01027-6","article-title":"Renal dysfunction associated with finerenone\u2014a pharmacovigilance analysis","volume":"81","author":"Rajak","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025052606264278600_bib153","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/dom.15518","article-title":"Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: a multicentre, randomized, double-blind, placebo-controlled, phase I trial","volume":"26","author":"Bornstein","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025052606264278600_bib154","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejim.2024.03.021","article-title":"Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: a population-based analysis","volume":"125","author":"Jim\u00e9nez-Marrero","year":"2024","journal-title":"Eur J Inter Med"},{"key":"2025052606264278600_bib155","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.hipert.2023.11.005","article-title":"Renin\u2013angiotensin\u2013aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial","volume":"41","author":"Garc\u00eda-Prieto","year":"2024","journal-title":"Hipertens Riesgo Vasc"},{"key":"2025052606264278600_bib156","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1159\/000531102","article-title":"Discontinuation of renin-angiotensin-aldosterone system inhibitors secondary to hyperkalemia translates into higher cardiorenal outcomes","volume":"54","author":"An","year":"2023","journal-title":"Am J Nephrol"},{"key":"2025052606264278600_bib157","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1007\/s12325-023-02518-w","article-title":"Real-world modifications of renin-angiotensin-aldosterone system inhibitors in patients with hyperkalemia initiating sodium zirconium cyclosilicate therapy: the OPTIMIZE I study","volume":"40","author":"Agiro","year":"2023","journal-title":"Adv Ther"},{"key":"2025052606264278600_bib158","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000530988","article-title":"Documented adverse drug reactions and discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease","volume":"54","author":"Gregg","year":"2023","journal-title":"Am J Nephrol"},{"key":"2025052606264278600_bib159","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000533753","article-title":"Maintaining renin-angiotensin-aldosterone system inhibitor treatment with patiromer in hyperkalaemic chronic kidney disease patients: comparison of a propensity-matched real-world population with AMETHYST-DN","volume":"54","author":"Chinnadurai","year":"2023","journal-title":"Am J Nephrol"},{"key":"2025052606264278600_bib160","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1681\/ASN.20233411S1857a","article-title":"Interim results from FINE-REAL: a prospective study providing insights into the use of finerenone in routine clinical settings","volume":"34","author":"Nicholas","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025052606264278600_bib161","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/87551225231168543","article-title":"A retrospective analysis of sacubitril\/valsartan in heart failure and chronic kidney disease","volume":"39","author":"McFarland","year":"2023","journal-title":"J Pharm Technol"},{"key":"2025052606264278600_bib162","doi-asserted-by":"publisher","first-page":"2222841","DOI":"10.1080\/0886022X.2023.2222841","article-title":"Effects of sacubitril-valsartan in patients undergoing maintenance dialysis","volume":"45","author":"Ding","year":"2023","journal-title":"Ren Fail"},{"key":"2025052606264278600_bib163","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.ihj.2023.11.105","article-title":"Effect of fineronone on heart failure outcomes in type 2 diabetes with chronic kidney disease: an early Indian experience","volume":"75","author":"Jariwala","year":"2023","journal-title":"Indian Heart J"},{"key":"2025052606264278600_bib164","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.jval.2023.09.535","article-title":"EE268 healthcare costs and all-cause mortality following a hyperkalemia event and reduction of RAASi therapy in Sweden","volume":"26","author":"Svensson","year":"2023","journal-title":"Value Health"},{"key":"2025052606264278600_bib165","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"2025052606264278600_bib166","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3109\/08860220903150312","article-title":"Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease","volume":"31","author":"Guney","year":"2009","journal-title":"Ren Fail"},{"key":"2025052606264278600_bib167","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025052606264278600_bib168","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/eurheartj\/ehab724.0895","article-title":"The risks and benefits of spironolactone use in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease","volume":"42","author":"Obertynska","year":"2021","journal-title":"Eur Heart J"},{"key":"2025052606264278600_bib169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc11872","article-title":"Severe hyperkalemia requiring hospitalization: predictors of mortality","volume":"16","author":"An","year":"2012","journal-title":"Crit Care"},{"key":"2025052606264278600_bib170","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1053\/j.ackd.2017.06.004","article-title":"Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes","volume":"24","author":"Gilligan","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025052606264278600_bib171","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11154-016-9384-x","article-title":"Updates in hyperkalemia: outcomes and therapeutic strategies","volume":"18","author":"Kovesdy","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"2025052606264278600_bib172","first-page":"gfae010","article-title":"Outcomes for clinical trials involving adults with chronic kidney disease: a multinational Delphi survey involving patients, caregivers and health professionals","author":"Matus Gonzalez","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025052606264278600_bib173","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0002-9343(00)00496-4","article-title":"Drug-induced hyperkalemia: old culprits and new offenders","volume":"109","author":"Perazella","year":"2000","journal-title":"Am J Med"},{"key":"2025052606264278600_bib174","first-page":"202","article-title":"The clinical and economic burden of hyperkalemia on medicare and commercial payers","volume":"10","author":"Fitch","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"2025052606264278600_bib175","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12325-021-01927-z","article-title":"A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives","volume":"39","author":"Evans","year":"2022","journal-title":"Adv Ther"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf127\/63029817\/sfaf127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/5\/sfaf127\/63029817\/sfaf127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/5\/sfaf127\/63029817\/sfaf127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T06:26:53Z","timestamp":1748240813000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf127\/8122114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":175,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf127","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,29]]},"article-number":"sfaf127"}}